New Therapies for Advanced Thyroid Cancer

被引：194

作者：

Laha, Diprajan ^{[1
]}

Nilubol, Naris ^{[1
]}

Boufraqech, Myriem ^{[1
]}

机构：

[1] NCI, Surg Oncol Program, NIH, Bethesda, MD 20892 USA

来源：

FRONTIERS IN ENDOCRINOLOGY | 2020年 / 11卷

关键词：

thyroid cancer; targeted therapies; advanced thyroid cancer; RAI-refractory; immunotherapy; ASSOCIATION MANAGEMENT GUIDELINES; BRAF MUTATIONS; PHOSPHATIDYLINOSITOL; 3-KINASE/AKT; THYROTROPIN SUPPRESSION; ANTITUMOR ACTIVITIES; GENETIC ALTERATIONS; RADIOACTIVE IODINE; SIGNALING PATHWAY; LENVATINIB E7080; ADULT PATIENTS;

D O I：

10.3389/fendo.2020.00082

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Thyroid cancer is the most common endocrine cancer. The discovery of new biomarkers for thyroid cancer has significantly improved the understanding of the molecular pathogenesis of thyroid cancer, thus allowing more personalized treatments for patients with thyroid cancer. Most of the recently discovered targeted therapies inhibit the known oncogenic mechanisms in thyroid cancer initiation and progression such as MAPK pathway, PI3K/Akt-mTOR pathways, or VEGF. Despite the significant advances in molecular testing and the discoveries of new and promising therapeutics, effective treatments for advanced and metastatic, iodine-refractory thyroid cancer are still lacking. Here, we aim to summarize the current understanding of the genetic alterations and the dysregulated pathways in thyroid cancer and to discuss the most recent targeted therapies and immunotherapy for advanced thyroid cancer with a promising anti-tumor activity and clinical benefit.

引用

页数：9

共 69 条

[1] Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 [J].

Ball, Douglas W. ;

Jin, Ning ;

Rosen, D. Marc ;

Dackiw, Alan ;

Sidransky, David ;

Xing, Mingzhao ;

Nelkin, Barry D. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (12) :4712-4718

[2] Benefits of Thyrotropin Suppression Versus the Risks of Adverse Effects in Differentiated Thyroid Cancer [J].

Biondi, Bernadette ;

Cooper, David S. .

THYROID, 2010, 20 (02) :135-146

[3] Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma [J].

Bollag, Gideon ;

Hirth, Peter ;

Tsai, James ;

Zhang, Jiazhong ;

Ibrahim, Prabha N. ;

Cho, Hanna ;

Spevak, Wayne ;

Zhang, Chao ;

Zhang, Ying ;

Habets, Gaston ;

Burton, ElizabethA. ;

Wong, Bernice ;

Tsang, Garson ;

West, Brian L. ;

Powell, Ben ;

Shellooe, Rafe ;

Marimuthu, Adhirai ;

Nguyen, Hoa ;

Zhang, Kam Y. J. ;

Artis, Dean R. ;

Schlessinger, Joseph ;

Su, Fei ;

Higgins, Brian ;

Iyer, Raman ;

D'Andrea, Kurt ;

Koehler, Astrid ;

Stumm, Michael ;

Lin, Paul S. ;

Lee, Richard J. ;

Grippo, Joseph ;

Puzanov, Igor ;

Kim, Kevin B. ;

Ribas, Antoni ;

McArthur, Grant A. ;

Sosman, Jeffrey A. ;

Chapman, Paul B. ;

Flaherty, Keith T. ;

Xu, Xiaowei ;

Nathanson, Katherine L. ;

Nolop, Keith .

NATURE, 2010, 467 (7315) :596-599

[4] Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases [J].

Bonhomme, Benjamin ;

Godbert, Yann ;

Perot, Gaelle ;

Al Ghuzlan, Abir ;

Bardet, Stephane ;

Belleannee, Genevieve ;

Criniere, Lise ;

Do Cao, Christine ;

Fouilloux, Genevieve ;

Guyetant, Serge ;

Kelly, Antony ;

Leboulleux, Sophie ;

Buffet, Camille ;

Leteurtre, Emmanuelle ;

Michels, Jean-Jacques ;

Tissier, Frederique ;

Toubert, Marie-Elisabeth ;

Wassef, Michel ;

Pinard, Clemence ;

Hostein, Isabelle ;

Soubeyran, Isabelle .

THYROID, 2017, 27 (05) :682-692

[5]

Brabant G, 2004, MMW Fortschr Med, V146, P30

[6]

Brabant G, 2004, MMW-FORTSCH MEDIZIN, V146, P30

[7] Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer [J].

Brauner, Eran ;

Gunda, Viswanath ;

Vanden Borre, Pierre ;

Zurakowski, David ;

Kim, Yon Seon ;

Dennett, Kate Virginia ;

Amin, Salma ;

Freeman, Gordon James ;

Parangi, Sareh .

ONCOTARGET, 2016, 7 (13) :17194-17211

[8] Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial [J].

Brose, Marcia S. ;

Cabanillas, Maria E. ;

Cohen, Ezra E. W. ;

Wirth, Lori J. ;

Riehl, Todd ;

Yue, Huibin ;

Sherman, Steven I. ;

Sherman, Eric J. .

LANCET ONCOLOGY, 2016, 17 (09) :1272-1282

[9] Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial [J].

Brose, Marcia S. ;

Nutting, Christopher M. ;

Jarzab, Barbara ;

Elisei, Rossella ;

Siena, Salvatore ;

Bastholt, Lars ;

de la Fouchardiere, Christelle ;

Pacini, Furio ;

Paschke, Ralf ;

Shong, Young Kee ;

Sherman, Steven I. ;

Smit, Johannes W. A. ;

Chung, John ;

Kappeler, Christian ;

Pena, Carol ;

Molnar, Istvan ;

Schlumberger, Martin J. .

LANCET, 2014, 384 (9940) :319-328

[10] Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial [J].

Brown, Sarah R. ;

Hall, Andrew ;

Buckley, Hannah L. ;

Flanagan, Louise ;

de Castro, David Gonzalez ;

Farnell, Kate ;

Moss, Laura ;

Gregory, Rebecca ;

Newbold, Kate ;

Du, Yong ;

Flux, Glenn ;

Wadsley, Jonathan .

BMC CANCER, 2019, 19 (1)

← 1 2 3 4 5 6 7 →